Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 11 of 24, showing 10 Applications out of 238 total, starting on record 101, ending on 110

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

101.

ECCT/21/09/08   GBT133_Inclacumab Open-Label
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Bernhards Ragama Ogutu
3. Videlis N Nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
22-03-2022 View

102.

ECCT/21/12/05   131 Inclacumab Ph 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N Nduba
4. Prof. Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
22-03-2022 View

103.

ECCT/21/11/07   lidERA
    A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTORPOSITIVE, HER2-NEGATIVE EARLY BREAST CANCER   
Principal Investigator(s)
1. Fredrick Asirwa Chite
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Aga Khan University Hospital (Nairobi City county)
 
27-03-2022 View

104.

ECCT/22/01/03   lidERA
    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Aga Khan University Hospital (Nairobi City county)
 
08-05-2022 View

105.

ECCT/22/01/05   STEP-Mag Trial
    Simplified Treatment for Eclampsia Prevention using Magnesium sulfate:  A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial)   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Wamalwa Kijana TRH (Trans Nzoia county)
2. Mama Lucy Kibaki Hospital (Nairobi City county)
3. Mbagathi County referral Hospital (Nairobi City county)
 
15-05-2022 View

106.

ECCT/22/02/01   An Open label Inclacumab study
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital. (Nairobi City county)
6. Strathmore University Medical Centre (Nairobi City county)
 
16-05-2022 View

107.

ECCT/22/01/04   SKYSCRAPER 07
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Mansoor Saleh
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
22-05-2022 View

108.

ECCT/22/03/10   Solidarity Trial Vaccines
    Solidarity Trial Vaccines: An international randomised trial of candidate vaccines against COVID-19   
Principal Investigator(s)
1. Ayallo, John Mark O, AYALLO
2. Prof KAWANGO AGOT AGOT
3. DR. LUCAS TINA OTIENO OTIENO
4. DR.MARICIANA ONONO ONONO
5. DR.JANET OYIEKO OYIEKO
6. DR.Fredrick Kipyego Sawe SAWE
7. DR. MICHAEL M MUTUA Mutua
8. Dr Joshua Kimani KIMANI
9. DR. IRENE A. MUGENYA MUGENYA
Site(s) in Kenya
1. SWOP (Nairobi City county)
2. K-IRDO –KISUMU (Kisumu county)
3. VIBRI- VICTORIA BIOMEDICAL RESEARCH INSTITUTE –KISUMU (Kisumu county)
4. KEMRI-CENTRE FOR MICROBIOLOGY RESEARCH (CMR) LUMUMBA –KISUMU (Kisumu county)
5. KEMRI –CENTRE FOR CLINICAL RESEARCH BUTERE(CCR) (Kakamega county)
6. Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) (Kericho county)
7. UNIVERSITY OF NAIROBI- KAVI- KANGEMI (Nairobi City county)
8. UNIVERSITY OF NAIROBI- KAVI- KNH (Nairobi City county)
 
23-05-2022 View

109.

ECCT/22/03/01   The \"NOVATION-1\" Trial
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19   
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. KEMRI Kericho (Kericho county)
4. KEMRI Siaya (Kisumu county)
5. Kenyatta National Hospital (Nairobi City county)
 
27-05-2022 View

110.

ECCT/22/03/09   GBT 132-Inclacumub PH3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Videlis N Nduba
2. Bernhards Ragama Ogutu
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. KEMRI/CRDR (Nairobi City county)
3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
4. Strathmore University Medical Centre (Nairobi City county)
 
30-05-2022 View